Alkermes (NASDAQ:ALKS – Get Free Report) and INmune Bio (NASDAQ:INMB – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings for Alkermes and INmune Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alkermes | 1 | 5 | 12 | 1 | 2.68 |
| INmune Bio | 1 | 0 | 0 | 1 | 2.50 |
Alkermes currently has a consensus price target of $54.47, suggesting a potential upside of 26.76%. Given Alkermes’ stronger consensus rating and higher probable upside, analysts clearly believe Alkermes is more favorable than INmune Bio.
Earnings and Valuation
This table compares Alkermes and INmune Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alkermes | $1.48 billion | 4.88 | $241.66 million | $0.38 | 113.08 |
| INmune Bio | $50,000.00 | 854.70 | -$45.93 million | ($0.67) | -2.30 |
Alkermes has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Alkermes has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Profitability
This table compares Alkermes and INmune Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alkermes | 3.96% | 4.15% | 2.19% |
| INmune Bio | N/A | -82.87% | -62.23% |
Insider and Institutional Ownership
95.2% of Alkermes shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 21.4% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Alkermes beats INmune Bio on 10 of the 13 factors compared between the two stocks.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
About INmune Bio
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
